KRAS and neoplasm: In total, there were 32 patients with microclonal mutations, of which 31 (54.4%) had at least one mutation in KRAS, NRAS, FLT3, and/or PTPN11. We assessed intra-sample tumor microheterogeneity and identified 16 patients with multiple microclonal mutations, including 10 patients carrying mutations in both KRAS and NRAS and 4 patients with mutations in at least 3 of the genes analyzed (Figure 4, Figure S8, Table S3).